Insight Molecular Diagnostics updated its expected cash burn to approximately $8 million per quarter for the second half of 2026, up from a prior estimate of roughly $6 million, primarily due to costs tied to completing the regulatory review process, registry activities, and commercial launch preparations for GraftAssureDx. CFO Andrea James noted that the second quarter's $10 million cash burn was the high watermark for the foreseeable future, while the adjusted EBITDA loss narrowed sequentially to $7.8 million. CEO Joshua Riggs said the company continues to target FDA marketing authorization for GraftAssureDx later this year and highlighted that Medicare's expanded reimbursement guidelines, which increase surveillance from 8 to 14 tests in the first three years post kidney transplant, strengthen the economic case for the test. Management also pointed to levers such as registry acceleration and reimbursed Nashville lab testing at $2,753 per result to extend its cash runway.
Insight Molecular Diagnostics Inc.Cash burn increased to ~$8M per quarter in H2 2026, up from prior estimate, though adjusted EBITDA loss narrowed.